A phase I trial of PSA-activated PSA-PAH1 [PRX 302; PORxin; Protox Therapeutics] therapy for locally recurrent prostate cancer without metastases after primary radiation therapy.

Trial Profile

A phase I trial of PSA-activated PSA-PAH1 [PRX 302; PORxin; Protox Therapeutics] therapy for locally recurrent prostate cancer without metastases after primary radiation therapy.

Completed
Phase of Trial: Phase I

Latest Information Update: 16 May 2013

At a glance

  • Drugs Topsalysin (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 03 Nov 2009 Actual end date (Jul 2008) added as reported by ClinicalTrials.gov.
    • 13 Feb 2008 Results will be presented on 14 February at the American Society of Clinical Oncology (ASCO) Genitourinary Cancer Symposium, held in San Francisco, California, USA.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top